Introduction {#section1-2192568217696695}
============

For many years, the use of iliac crest bone graft (ICBG) was a staple for most of the spine fusion procedures as an effective way to achieve solid fusion. However, studies have shown that ICBG harvest is associated with the increased patient morbidity, blood loss, and length of stay.^[@bibr1-2192568217696695]^ Since then, various classes of bone substitutes were developed to eliminate these complications.

Bone morphogenetic proteins (BMPs) were discovered by Marshall Urist in 1965, and are involved in tissue morphogenesis, cell differentiation, normal skeletogenesis, cancer and several other processes.^[@bibr2-2192568217696695],[@bibr3-2192568217696695]^ Large number of studies have explored BMP2 capabilities in promoting osteogenesis and bone formation in vitro and in vivo. In an animal study, Sandhu et al^[@bibr4-2192568217696695]^ demonstrated that group with rhBMP2 had earlier fusion, better bone formation observed via histology and biomechanical properties when compared with the autograft group. In 2002, rhBMP2 saw an increase in the popularity after Burkus et al^[@bibr5-2192568217696695]^ reported similar fusion rates between the ICBG and rhBMP2 in the anterior lumbar fusion. Initially, rhBMP2 was approved for single-level anterior fusion approach,^[@bibr6-2192568217696695]^ and subsequently extended for revision surgeries including the posterolateral fusion. High fusion rates led to its "off-label" use with 30% of the surgeries being posterior lumbar interbody fusion (PLIF) and transforaminal lumbar interbody fusions (TLIF).^[@bibr7-2192568217696695],[@bibr8-2192568217696695]^ Although the use of rhBMP2 led to high fusion rates,^[@bibr9-2192568217696695]^ there is a large body of literature on potential adverse events associated with its application.^[@bibr10-2192568217696695][@bibr11-2192568217696695][@bibr12-2192568217696695][@bibr13-2192568217696695]--[@bibr14-2192568217696695]^ Two recent meta-analyses challenged the benefits and adverse events associated with rhBMP2.^[@bibr15-2192568217696695],[@bibr16-2192568217696695]^ They reported that the previous data on complications was misrepresented, inconclusive, and often biased by industry-sponsored clinical trials.^[@bibr15-2192568217696695],[@bibr16-2192568217696695]^

The aim of our study was to compare the complication rates in patients receiving rhBMP2 for PLIF with those without rhBMP2, using a large insurance database.

Materials and Methods {#section2-2192568217696695}
=====================

Data Extraction {#section3-2192568217696695}
---------------

Our study was deemed exempt from institutional review board review as all patient information was deidentified and we did not receive individual patient information. Data was derived from the Orthopaedic subset of Medicare database (January 2005 to December 2010) within the PearlDiver Patient Records Database (<http://www.pearldiverinc.com>; Pearl-Diver Inc, Fort Wayne, IN). The database was queried using ICD-9 (International Statistical Classification of Diseases, 9th Revision) diagnosis and Current Procedural Terminology (CPT) codes. We used CPT-22630 (arthrodesis performed using a posterior interbody technique that includes laminectomy and discectomy to prepare the interspace at a single level) to isolate patients undergoing PLIF procedure. ICD-9 P-8452 (insertion of bone morphogenetic protein) was then added as an inclusion and exclusion criteria to create 2 cohorts: patients undergoing PLIF with rhBMP2 and PLIF without rhBMP2. The specific complications were isolated within 1 year postoperatively. Complication groups included cardiac, pulmonary, thromboembolism, neuralgia and radiculitis, lumbosacral neuritis, pseudarthrosis, postoperative infection, hemorrhage and hematoma, wound, central nervous system, and urinary tract (include acute kidney failure and postoperative complications, [Table 1](#table1-2192568217696695){ref-type="table"}). Complication rate of each given complication were calculated as following: the number of PLIF patients (with or without rhBMP2) with a specific complication/number of PLIF patients (with or without rhBMP2) × 100 (to create percentage).

###### 

ICD-9-D Complication Codes.

![](10.1177_2192568217696695-table1)

  Complication Group           ICD-9-D codes
  ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cardiac                      ICD-9-D-9971, ICD-9-D-4100, ICD-9-D-4101, ICD-9-D-4102, ICD-9-D-4103, ICD-9-D-4104, ICD-9-D- 4105, ICD-9-D-4106, ICD-9-D-4107, ICD-9-D-4108 and ICD-9-D-4109
  Pulmonary                    ICD-9-D-41511, ICD-9-D-41512, ICD-9-D- 41513, ICD-9-D-41514, ICD-9-D-41515, ICD-9-D-41516, ICD-9-D-41517, ICD-9-D-41518, ICD-9-D-41519, ICD-9-D-9973, ICD-9-D-51881, ICD-9-D-51882, ICD-9-D-51883, ICD-9-D-51884 and ICD-9-D-51885
  Thromboembolism              ICD-9-D-4530, ICD-9-D-4531, ICD-9-D-4532, ICD-9-D-4533, ICD-9-D-4534, ICD-9-D-4535, ICD-9-D-4536, ICD-9-D-4537, ICD-9-D-4538 and ICD-9-D-4539
  Neuralgia, and radiculitis   ICD-9-D-7292
  Lumbosacral neuritis         ICD-9-D-7244
  Pseudarthrosis               ICD-9-D-73382
  Postoperative infections     ICD-9-D-99851and ICD-9-D-99859
  Hemorrhages and hematoma     ICD-9-D-99811, ICD-9-D-99812 and ICD-9-D-99813
  Wound                        ICD-9-D-99831, ICD-9-D-99832 and ICD-9-D-99883
  Neurological system          ICD-9-D-99700, ICD-9-D-99701, ICD-9-D-99702, ICD-9-D-99703, ICD-9-D-99704, ICD-9-D-99705, ICD-9-D-99706, ICD-9-D-99707, ICD-9-D-99708 and ICD-9-D-99709
  Urinary tract                ICD-9-D-5845, ICD-9-D-5846, ICD-9-D-5847, ICD-9-D-5848, ICD-9-D-5849 and ICD-9-D-9975

Abbreviation: ICD-9, International Classification of Diseases, 9th Revision.

Statistical Analysis {#section4-2192568217696695}
--------------------

Chi-square was used to compare the complication rates between the rhBMP2 and non-rhBMP2 groups. SPSS statistical software (IBM Corporation, Armonk, NY) was used for the data analysis. Statistical significance was set at *P* ≤ .05.

Results {#section5-2192568217696695}
=======

A total of 8609 patients within the Medicare database underwent PLIF procedure between 2005 and 2010. Of this subset of patients, 5497(63.9%) had a PLIF surgery without rhBMP2 and 3112 (36.1%) had it with rhBMP2. Demographics were not part of this analysis; however, all the patients were aged ≥65 years.

Complication rates were significantly higher in the non-rhBMP2 group (0.95%-10.99%) compared with the rhBMP2 group (0.45%-7.68%, *P* ≤ .05).

The number of complications significantly higher in non-rhBMP2 group included postoperative infections (2.86% non-rhBMP2 vs 2.09% rhBMP2), wound complication (2.31% non-rhBMP2 vs 1.35% rhBMP2), urinary tract (4.73% non-rhBMP2 vs 3.54% rhBMP2), and lumbosacral neuritis (10.99% non-rhBMP2 vs 7.68% rhBMP2). Similarly, significant differences were observed for cardiac complications in the non-rhBMP2 group (3.75%) when compared with the rhBMP2 group (2.22%, *P* ≤ .05, [Table 2](#table2-2192568217696695){ref-type="table"}). Pulmonary complications were also significantly higher in non-rhBMP2 patients (4.35%) compared with 3.34% in rhBMP2 patients. Pseudarthrosis rates were 1.57% in the PLIF and rhBMP2 group compared to the 0.95% in the PLIF and non-rhBMP2 group (*P* = .009). No significant differences were noted between the groups for thromboembolism, neuralgia and radiculitis, hemorrhage and hematoma and central nervous system complications (*P* \> .05, [Table 2](#table2-2192568217696695){ref-type="table"}).

###### 

Complication Rates in PLIF With and Without rhBMP2, With Associated *P* Values.
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  Type of Complication          PLIF Without BMP   Complication Rate (%)   PLIF With BMP   Complication Rate (%)   *P*
  ----------------------------- ------------------ ----------------------- --------------- ----------------------- -------------
  Cardiac                       206                3.75                    69              2.22                    .0001
  Pulmonary                     239                4.35                    104             3.34                    .022
  Emboli/thrombosis             308                5.6                     188             6.04                    .40
  Neuralgia and radiculitis     172                3.13                    107             3.44                    .43
  Lumbosacral neuritis          604                10.99                   239             7.68                    7 × 10^−07^
  Pseudarthrosis                52                 0.95                    49              1.57                    .009
  Infections                    157                2.86                    65              2.09                    .03
  Hemorrhage and hematoma       114                2.07                    60              1.92                    .64
  Wound complication            127                2.31                    42              1.35                    .002
  Nervous system complication   36                 0.65                    14              0.45                    .22
  Urinary tract complications   260                4.73                    110             3.54                    .009

Abbreviations: PLIF, posterior lumbar interbody fusion; rhBMP2, recombinant human bone morphogenetic protein 2.

Discussion {#section6-2192568217696695}
==========

In our study, the use of rhBMP2 in PLIF procedures was not associated with an increased rate of complications compared to PLIF without rhBMP2. In fact, we found the rate of complication to be significantly higher in those individuals who underwent PLIF procedure without rhBMP2. On the other hand, Deyo et al^[@bibr14-2192568217696695]^ reported no significant difference in the complication rates between patients undergoing spinal fusion for stenosis with and without rhBMP2 and non-rhBMP2 within the Medicare database. A potential explanation for this discrepancy might be due to the follow-up period, in the study done by Deyo et al,^[@bibr14-2192568217696695]^ complication and reoperation rates were recorded within first 30 days.

The incidence of infection in our study was significantly lower in the rhBMP2 group. Similarly, Singh et al^[@bibr17-2192568217696695]^ reported a 2.1% infection rate in rhBMP2 group compared with 9.1% in the control group (*P* = .07).

In our study, pseudarthrosis rates were higher in rhBMP2 group, which is different from the previous reports that suggest decreases the rate of pseudarthrosis with rhBMP2.^[@bibr17-2192568217696695]^ An explanation for this may be the nature of the database and if this complication is coded, as well as our population profile, older individuals with lower bone density and osteoinductive activity. Furthermore, rhBMP2 tends to be used in more complex cases, which potentially carry a higher risk of pseudarthrosis.^[@bibr16-2192568217696695],[@bibr18-2192568217696695]^ Neurological and wound complications were lower in the rhBMP2 group.

Similar rates of hemorrhagic complications in our study are in accordance with previous literature.^[@bibr19-2192568217696695]^ In our study, no significant difference was found for thromboembolism, neuralgia and radiculitis, and other nervous system complications. Chrastil et al^[@bibr20-2192568217696695]^ conducted a systematic review on several complications with rhBMP2 use and reported the rates of postoperative radiculitis between 14% and 20% in patients undergoing PLIF/TLIF with rhBMP2 compared with 3% to 5% without rhBMP2.

There were several limitations to our study. This was a retrospective database study searched by ICD-9 and CPT codes and it is subject to failure in recording specific complications. Furthermore, previous medical history, clinical and radiographic outcomes, and rhBMP2 dose were not available limiting us to account for any confounding variables between the groups.

Despite these limitations, we believe that our study provides additional support to the notion that the rate of complications associated with rhBMP2 use in PLIF is lower than in PLIF procedures without rhBMP2. Further studies on biologics focusing on the mechanism of complications, optimal dosing and long-term outcomes are warranted.
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